NCT01597349

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 208 (actual)
• Sponsor: Avalo Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection. The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.

Conditions

• Acute Cough

Interventions

Type	Name	Description
DRUG	FP01	Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.

Timeline

• Start date: 2012-05-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-05-14
• Last updated: 2014-02-28

Locations

5 sites across 2 countries: Chile, Peru